Fisons Announces New Chief Executive

17 July 1994

Six months after Cedric Scroggs departed his post as chief executive at the UK pharmaceutical and scientific equipment company Fisons, a new appointment to the position has been announced. Fisons has named Stuart Wallis, a chartered accountant, as chief executive with effect from September 1, 1994. Mr Wallis is leaving Bowater, where he has been an executive director responsible for the company's European packaging and international packaging businesses.

It has been suggested that Mr Wallis was in line as successor to Bowater's current chief executive. Bowater's shares plummeted when the appointment was announced, but Fisons' share price, which has had a particularly bumpy ride in the past couple of years, did not move.

Patrick Egan, chairman of Fisons, said: "we are extremely pleased that Stuart Wallis will be joining us. He is a very experienced industrial executive and we much look forward to working with him." However, there have been some reservations concerning his lack of experience in the pharmaceutical field.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight